PE20220139A1 - Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar - Google Patents
Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiarInfo
- Publication number
- PE20220139A1 PE20220139A1 PE2021001329A PE2021001329A PE20220139A1 PE 20220139 A1 PE20220139 A1 PE 20220139A1 PE 2021001329 A PE2021001329 A PE 2021001329A PE 2021001329 A PE2021001329 A PE 2021001329A PE 20220139 A1 PE20220139 A1 PE 20220139A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halo
- cyano
- hydroxy
- hydrogen
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000001730 Familial dysautonomia Diseases 0.000 abstract 1
- 201000001638 Riley-Day syndrome Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- -1 thieno[3,2-b]pyridine derivative compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos derivados de tieno[3,2-b]piridina de Formula (I), o una forma de sal del mismo, donde: R1 se selecciona de fenilo y heteroarilo de 5-8 miembros, opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes R1a seleccionados independientemente; R1a se selecciona de ciano, halo, hidroxi, alquilo C1-6, halo-alquilo C1-6 y alcoxi C1-6; R3 se selecciona de hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y alquilo C1-6-amino, en donde cada alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 esta opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes R3a seleccionados independientemente, y en cada caso, pueden contener opcionalmente un carbono quiral de configuracion (R) o (S); R3a se selecciona de ciano, halo, hidroxi, oxo, alquilo C1-6, halo-alquilo C1-6, entre otros; R4 se selecciona de hidrogeno, ciano, halo, hidroxi, alquilo C1-6, halo-alquilo C1-6, entre otros; R5 se selecciona de hidrogeno, ciano, halo, hidroxi, alquilo C1-6, halo-alquilo C1-6, entre otros; R6 se selecciona de hidrogeno, halo y alquilo C1-6. Tambien se refiere a composiciones farmaceuticas. Dichos compuestos corresponden son utiles para mejorar el corte y empalme de pre-ARNm en una celula, para tratar o mejorar la disautonomia familiar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805283P | 2019-02-13 | 2019-02-13 | |
| PCT/US2020/017430 WO2020167628A1 (en) | 2019-02-13 | 2020-02-10 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220139A1 true PE20220139A1 (es) | 2022-01-27 |
Family
ID=69960696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001329A PE20220139A1 (es) | 2019-02-13 | 2020-02-10 | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12384797B2 (es) |
| EP (1) | EP3924049A1 (es) |
| JP (1) | JP7587511B2 (es) |
| KR (1) | KR20210137040A (es) |
| CN (1) | CN113795304A (es) |
| AU (1) | AU2020222881B2 (es) |
| BR (1) | BR112021015853A2 (es) |
| CA (1) | CA3129067A1 (es) |
| CL (1) | CL2021002137A1 (es) |
| CO (1) | CO2021010598A2 (es) |
| EA (1) | EA202192170A1 (es) |
| IL (1) | IL285399B2 (es) |
| MX (1) | MX2021009667A (es) |
| PE (1) | PE20220139A1 (es) |
| SG (1) | SG11202108519TA (es) |
| UA (1) | UA129890C2 (es) |
| WO (1) | WO2020167628A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021015853A2 (pt) | 2019-02-13 | 2021-10-05 | Ptc Therapeutics, Inc. | Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar |
| EP3924050A1 (en) | 2019-02-13 | 2021-12-22 | PTC Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| BR112022011364A2 (pt) * | 2019-12-12 | 2022-08-23 | Ptc Therapeutics Inc | Compostos para tratar disautonomia familiar |
| MX2022013856A (es) | 2020-05-13 | 2023-04-05 | Chdi Foundation Inc | Moduladores htt para tratar la enfermedad de huntington. |
| JP2024504587A (ja) * | 2021-01-14 | 2024-02-01 | ジョージタウン ユニバーシティ | Ｕｓｐ１３阻害剤及びその使用方法 |
| CN112920053B (zh) * | 2021-02-01 | 2022-07-01 | 暨明医药科技（苏州）有限公司 | 一种手性α-甲基芳乙胺的制备方法 |
| WO2022169868A1 (en) * | 2021-02-05 | 2022-08-11 | Ptc Therapeutics Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| US20240051968A1 (en) | 2021-02-05 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| US20250188091A1 (en) | 2021-06-03 | 2025-06-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pyridone compound having integrase inhibitory activity and pharmaceutical use thereof |
| EP4398987A4 (en) * | 2021-09-07 | 2025-07-09 | Ptc Therapeutics Inc | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| WO2023081857A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed pyridazine amine derivatives treating sca3 |
| JP2024540477A (ja) | 2021-11-17 | 2024-10-31 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | ハンチントン病を治療するためのｈｔｔモジュレータとしてのｎ－（２ｈ－インダゾール－５－イル）ピラジン－２－カルボキサミド誘導体及び類似化合物 |
| WO2023212237A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US20250304593A1 (en) | 2022-05-12 | 2025-10-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| CN119997954A (zh) * | 2022-06-22 | 2025-05-13 | Ptc医疗公司 | 用于治疗脊髓小脑性共济失调3型的化合物 |
| EP4568962A2 (en) * | 2022-08-09 | 2025-06-18 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| JP3126541B2 (ja) | 1993-03-26 | 2001-01-22 | 千寿製薬株式会社 | ベンゾチアゾール誘導体、その製法及びその用途 |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| JP2002501493A (ja) | 1997-04-22 | 2002-01-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃｒｆアンタゴニストのチオフェノピリジン類 |
| BR9814018A (pt) | 1997-11-11 | 2000-09-26 | Pfizer Prod Inc | Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| WO2005007083A2 (en) | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| WO2005033290A2 (en) | 2003-10-03 | 2005-04-14 | The General Hospital Corporation | Methods for altering mrna splicing and treating familial dysautonomia and other mechanistically related disorders |
| JP2009007341A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2014663A1 (de) | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
| NZ588011A (en) | 2008-03-05 | 2012-06-29 | Takeda Pharmaceutical | Heterocyclic compounds having glucagon antagonistic action useful for treating diabetes |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| US20130209549A1 (en) | 2010-07-21 | 2013-08-15 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
| US20130317045A1 (en) | 2010-09-01 | 2013-11-28 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| EP2867236B1 (en) | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| CA2900779C (en) | 2013-02-11 | 2021-10-26 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
| US20160002273A1 (en) | 2013-03-07 | 2016-01-07 | Glaxosmithkline Llc | Thieno[3,2-d]pyrimidine-6-carboxamides and analogues as sirtuin modulators |
| KR20230116945A (ko) | 2013-03-14 | 2023-08-04 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| WO2015005491A1 (ja) * | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
| RU2692634C2 (ru) | 2013-10-07 | 2019-06-25 | Академиш Зикенхойс Лейден Х.О.Д.Н. Люмк | Направляемое антисмысловым олигонуклеотидом удаление сайтов протеолитического расщепления, мутации hchwa-d и увеличенного числа тринуклеотидных повторов |
| KR102390370B1 (ko) | 2014-02-12 | 2022-04-26 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| CA2973949C (en) * | 2015-01-16 | 2023-07-11 | The General Hospital Corporation | Compounds for improving mrna splicing |
| HUE053943T2 (hu) | 2015-04-29 | 2021-08-30 | Janssen Pharmaceutica Nv | Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk |
| GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| EP3353303B1 (en) | 2015-09-25 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
| MX382671B (es) | 2015-12-10 | 2025-03-13 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| MX2019001239A (es) | 2016-08-03 | 2019-07-04 | Meiragtx Uk Ii Ltd | Deteccion de alto rendimiento basada en celulas para aptámeros. |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| CN114432318A (zh) | 2017-02-20 | 2022-05-06 | 国立大学法人京都大学 | 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法 |
| CA3082907A1 (en) | 2017-11-27 | 2019-05-31 | Coda Biotherapeutics, Inc. | Compositions and methods for neurological diseases |
| EP3894396A1 (en) | 2018-12-10 | 2021-10-20 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| CN109819066A (zh) | 2019-01-31 | 2019-05-28 | 平安科技（深圳）有限公司 | 一种基于地理位置的智能解析域名方法及装置 |
| BR112021015853A2 (pt) | 2019-02-13 | 2021-10-05 | Ptc Therapeutics, Inc. | Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar |
| CA3129609A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
| EP3924050A1 (en) | 2019-02-13 | 2021-12-22 | PTC Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| US20220056043A1 (en) | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
| EP3980539A1 (en) | 2019-06-06 | 2022-04-13 | F. Hoffmann-La Roche AG | Antisense oligonucleotides targeting atxn3 |
| KR102537214B1 (ko) | 2019-11-26 | 2023-05-31 | 주식회사 고영테크놀러지 | 자기 공명 이미지들에서 정중시상 평면을 결정하기 위한 방법 및 장치 |
| BR112022011364A2 (pt) | 2019-12-12 | 2022-08-23 | Ptc Therapeutics Inc | Compostos para tratar disautonomia familiar |
| WO2021142351A1 (en) | 2020-01-08 | 2021-07-15 | The Broad Institute, Inc. | Multi-functional chimeric molecules |
| WO2022169868A1 (en) | 2021-02-05 | 2022-08-11 | Ptc Therapeutics Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| US20240051968A1 (en) | 2021-02-05 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| EP4288441A4 (en) | 2021-02-05 | 2024-12-11 | PTC Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| CA3214751A1 (en) | 2021-04-09 | 2022-10-27 | Amit Choudhary | Bifunctional molecules for selective modification of target substrates |
| MX2024002887A (es) | 2021-09-07 | 2024-05-28 | Ptc Therapeutics Inc | Metodos para tratar enfermedades neurodegenerativas. |
| EP4398986A4 (en) | 2021-09-07 | 2025-07-09 | Ptc Therapeutics Inc | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP4398987A4 (en) | 2021-09-07 | 2025-07-09 | Ptc Therapeutics Inc | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| WO2023081857A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed pyridazine amine derivatives treating sca3 |
| CN119997954A (zh) | 2022-06-22 | 2025-05-13 | Ptc医疗公司 | 用于治疗脊髓小脑性共济失调3型的化合物 |
-
2020
- 2020-02-10 BR BR112021015853-7A patent/BR112021015853A2/pt unknown
- 2020-02-10 UA UAA202105103A patent/UA129890C2/uk unknown
- 2020-02-10 CA CA3129067A patent/CA3129067A1/en active Pending
- 2020-02-10 SG SG11202108519TA patent/SG11202108519TA/en unknown
- 2020-02-10 AU AU2020222881A patent/AU2020222881B2/en active Active
- 2020-02-10 WO PCT/US2020/017430 patent/WO2020167628A1/en not_active Ceased
- 2020-02-10 EP EP20714017.9A patent/EP3924049A1/en active Pending
- 2020-02-10 US US17/430,511 patent/US12384797B2/en active Active
- 2020-02-10 JP JP2021547446A patent/JP7587511B2/ja active Active
- 2020-02-10 PE PE2021001329A patent/PE20220139A1/es unknown
- 2020-02-10 CN CN202080028449.2A patent/CN113795304A/zh active Pending
- 2020-02-10 EA EA202192170A patent/EA202192170A1/ru unknown
- 2020-02-10 MX MX2021009667A patent/MX2021009667A/es unknown
- 2020-02-10 KR KR1020217028864A patent/KR20210137040A/ko active Pending
- 2020-02-10 IL IL285399A patent/IL285399B2/en unknown
-
2021
- 2021-08-12 CO CONC2021/0010598A patent/CO2021010598A2/es unknown
- 2021-08-12 CL CL2021002137A patent/CL2021002137A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL285399B1 (en) | 2025-02-01 |
| EA202192170A1 (ru) | 2021-11-15 |
| IL285399B2 (en) | 2025-06-01 |
| EP3924049A1 (en) | 2021-12-22 |
| US12384797B2 (en) | 2025-08-12 |
| KR20210137040A (ko) | 2021-11-17 |
| UA129890C2 (uk) | 2025-09-03 |
| AU2020222881B2 (en) | 2025-07-10 |
| JP7587511B2 (ja) | 2024-11-20 |
| CA3129067A1 (en) | 2020-08-20 |
| AU2020222881A1 (en) | 2021-09-09 |
| CL2021002137A1 (es) | 2022-02-25 |
| BR112021015853A2 (pt) | 2021-10-05 |
| US20220135586A1 (en) | 2022-05-05 |
| IL285399A (en) | 2021-09-30 |
| SG11202108519TA (en) | 2021-09-29 |
| WO2020167628A1 (en) | 2020-08-20 |
| MX2021009667A (es) | 2021-12-10 |
| JP2022520822A (ja) | 2022-04-01 |
| CN113795304A (zh) | 2021-12-14 |
| CO2021010598A2 (es) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220139A1 (es) | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar | |
| AR082154A1 (es) | DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4 | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| MX381849B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. | |
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| BR112014002675A2 (pt) | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| PE20181272A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR088218A1 (es) | Compuestos heterociclicos utiles como inhibidores de pi3k | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| UY31638A1 (es) | Furo[3,2-c]piridina y tieno[3,2-c]piridinas | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a |